VEGFR1 Blockade Reverses Advanced Diabetic Kidney Damage in Mice

Diabetic kidney disease remains the primary driver of chronic kidney failure, necessitating aggressive management of glycemic control and blood pressure to slow progression [1, 2]. While the vascular endothelial growth factor (VEGF) pathway is a known regulator of glomerular filtration and microvascular integrity, clinical attempts to modulate these signals have often yielded inconsistent outcomes [3, 4]. Recent phase 2 trials targeting related pathways have failed to significantly reduce albuminuria (the presence of excess albumin in the urine, a key clinical marker of kidney damage); for instance, the vascular endothelial growth factor B inhibitor CSL346 showed only a 4.0% difference in the urinary albumin-creatinine ratio compared to placebo (95% confidence interval, -14.7 to 26.8) [5]. Similarly, the interleukin-33 inhibitor tozorakimab demonstrated no significant benefit, with a 23% to 25% reduction in albuminuria compared to 22% in the placebo group [6]. Furthermore, systemic anti-angiogenic therapy is frequently complicated by hypertension, as seen with CSL346, which increased diastolic blood pressure by up to 5.3 mm Hg (p = 0.002) [5, 4]. A recent study now investigates whether selective targeting of vascular endothelial growth factor receptor 1 (VEGFR1) can move beyond disease stabilization to achieve the regression of established renal lesions [7].